Mealey's (May 27, 2021, 9:59 AM EDT) -- TRENTON, N.J. — A biopharmaceutical company violated federal securities laws by publicly misrepresenting the likelihood that its Type 1 diabetes treatment drug would gain U.S. Food and Drug Administration approval, which caused the company’s stock to trade at an artificially high rate until the alleged fraud was disclosed, a shareholder alleges in a complaint filed May 21 in New Jersey federal court....